TBS-5 / Acerus - LARVOL DELTA

Ecological versatility and biotechnological promise: Comprehensive characterization of the isolated thermophilic Bacillus strains. (PubMed, PLoS One) - "However, strains TBS35 and TBS40 were exceptions, growing at 37°C...Their resilience to extreme temperatures, pH levels, varied oxygen conditions, and diverse metabolic and genetic features emphasize their potential for biotechnological applications. These insights deepen our understanding of these species' ecological roles and highlight their potential industrial and environmental applications."

Journal • CAT

Streptomyces-mediated growth enhancement and Bacterial Panicle Blight disease suppression in rice plants under greenhouse conditions. (PubMed, J Biotechnol) - "Under greenhouse conditions, Streptomyces-treated plants showed improvement in rice plants' growth and grain yield and reduced the BPB disease severity. Results suggest that the S. corchorusii TKR8, S. corchorusii JAS2 and S. misionensis TBS5 should be promoted as biocontrol agents against B. glumae and bioformulations for rice crops."

Journal

Timed barium swallow for assessing long-term treatment response in patients with achalasia: Absolute cutoff versus percent change - A cross-sectional analytic study. (PubMed, Neurogastroenterol Motil) - "The results show that 3% percent improvement in pre- and post-treatment barium height at 5 minutes rather than absolute cutoff value of <5 cm on post-treatment TBS is a better indicator of treatment success in achalasia patients. These findings indicate the need for reassessment of tools to identify treatment response."

Clinical • Journal • Rare Diseases

Loss of Depotentiation in Focal Dystonia (clinicaltrials.gov) - P=N/A; N=6; Terminated; Sponsor: National Institute of Neurological Disorders and Stroke (NINDS); Phase classification: P1 ➔ P=N/A

Phase classification • CNS Disorders • Dystonia • Movement Disorders

Loss of Depotentiation in Focal Dystonia (clinicaltrials.gov) - P1; N=6; Terminated; Sponsor: National Institute of Neurological Disorders and Stroke (NINDS); N=40 ➔ 6; Trial completion date: Dec 2021 ➔ Apr 2020; Recruiting ➔ Terminated; Trial primary completion date: Dec 2021 ➔ Apr 2020; PI leaving the NIH

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

Loss of Depotentiation in Focal Dystonia (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: National Institute of Neurological Disorders and Stroke (NINDS); Trial completion date: Dec 2019 ➔ Dec 2021; Trial primary completion date: Dec 2019 ➔ Dec 2021

Trial completion date • Trial primary completion date